Processa Pharmaceuticals, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Processa Pharmaceuticals, Inc. (PCSA) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $790.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2021-11-12
- 2021-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $790.00K.
- 2021-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $790.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2021-09-30 | $790.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $790.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |